COMMUNIQUÉS West-GlobeNewswire

Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026
22/10/2026
NORWOOD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data [...]
Rgenta Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Trial Design for RGT-61159 in Patients with Adenoid Cystic Carcinoma (ACC)
22/10/2026
Phase 3 trial alignment paves path toward New Drug Application and potential approval of RGT-61159, an oral small molecule targeting the MYB oncogene Prior preliminary data in patients treated at or below recommended [...]
Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
22/10/2026
CLEARWATER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion ® and the AYON Body [...]
Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent
22/10/2026
GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. Georgiamune to receive $45 million in upfront and near-term payments, as part of [...]
Annovis to Attend the CTAD 2026 with Three Presentations
22/10/2026
MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Ignite Proteomics Enters Breast Cancer Research Collaboration with Leading Cancer Center
22/10/2026
Research Will Apply Ignite's RPPA-Based Proteomic Test to Study Treatment Response and Resistance GOLDEN, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ignite Proteomics, Inc. (“Ignite” or the “Company”), a precision [...]
Senseonics Holdings, Inc. to Participate in Upcoming Investor Conferences
22/10/2026
GERMANTOWN, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose [...]
Celularity Regains Compliance with Nasdaq Periodic Reporting Requirement
22/10/2026
Nasdaq closes reporting deficiency following filing of second-quarter 2026 Form 10-Q FLORHAM PARK, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative [...]
LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
22/10/2026
SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ ® (aceclidine ophthalmologic solution) 1. [...]
Eos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches “Team Speedy” to Let the Public Follow Its Longest-Lived Mouse
22/10/2026
In naturally aged mice treated from 80 weeks of age and followed until natural death, once-weekly PTC-2105 (25 mg/kg) significantly increased overall survival versus saline (log-rank p = 0.0142) “Speedy,” a PTC-2105- [...]
Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility
22/10/2026
– Company’s achievement of pre-defined revenue, growth and operational milestones increases facility commitment by $15.0 million – – Capital now available to support continued growth of the YCANTH® business and [...]
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
22/10/2026
Seven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial mechanism of action for rilparencel One clinical abstract presents a new [...]
Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026
22/10/2026
PITTSBURGH, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2026 financial results on Monday, November 2, 2026, prior to the [...]
MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study
22/10/2026
Positive IND-Enabling Proof-of-Concept Study Demonstrates Sustained Efficacy Without Observed Tolerance, Reduced Inflammation-Associated Swelling, and Favorable Tolerability MIAMI, Oct. 22, 2026 (GLOBE NEWSWIRE) -- MIRA [...]
AskBio Announces 5 Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress
22/10/2026
Durham, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Five poster presentations will highlight exciting progress in AskBio’s adeno-associated virus (AAV) manufacturing technologies AskBio Inc. (AskBio), a gene therapy company [...]
Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026
22/10/2026
WOBURN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will [...]
Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026
22/10/2026
STOUGHTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood [...]
Rectify to Present Translational Data Supporting RTY-406 as a Transformative Therapy for PSC and Other Hepatobiliary Diseases
22/10/2026
BOSTON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, Inc ., (“Rectify”) a biotechnology company pioneering positive functional modulators (PFMs) that restore and enhance membrane protein function, today [...]
SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases
22/10/2026
Intravenous SCY-247 was generally well tolerated in healthy participants, with no drug-related serious adverse events Once-daily intravenous doses of 50 mg or higher achieved exposures at or above the target identified [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum